Unknown

Dataset Information

0

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.


ABSTRACT: In a prior study, lumacaftor/ivacaftor treatment (?28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function.To evaluate an optimized lumacaftor/ivacaftor dosing regimen with a longer duration in a cohort of patients heterozygous for F508del-CFTR.Patients aged 18 years or older with a confirmed CF diagnosis and percent predicted FEV1 (ppFEV1) of 40 to 90 were randomized to lumacaftor/ivacaftor (400 mg/250 mg every 12 h) or placebo daily for 56 days. Primary outcomes were change in ppFEV1 at Day 56 and safety. Other disease markers were evaluated.Of 126 patients, 119 (94.4%) completed the study. Lumacaftor/ivacaftor was well tolerated, although chest tightness and dyspnea occurred more frequently with active treatment than with placebo (27.4% vs. 14.3% and 14.5% vs. 6.3%, respectively). Mean (SD) ppFEV1 values at baseline were 62.9 (14.3) in the active treatment group and 60.1 (14.0) in the placebo group. Absolute changes in ppFEV1 (least squares mean [SE]) at Day 56 were -0.6 (0.8) percentage points in the active treatment group and -1.2 (0.8) percentage points in the placebo group (P?=?0.60). CF respiratory symptom scores in the active treatment group improved by a mean of 5.7 points versus a decrease of -0.8 in the placebo group (P?

SUBMITTER: Rowe SM 

PROVIDER: S-EPMC5461999 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.

Rowe Steven M SM   McColley Susanna A SA   Rietschel Ernst E   Li Xiaolei X   Bell Scott C SC   Konstan Michael W MW   Marigowda Gautham G   Waltz David D   Boyle Michael P MP  

Annals of the American Thoracic Society 20170201 2


<h4>Rationale</h4>In a prior study, lumacaftor/ivacaftor treatment (≤28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function.<h4>Objectives</h4>To evaluate an optimized lumacaftor/ivacaftor dosing regimen with a longer duration in a cohort of patients heterozygous for F508del-CFTR.<h4>Methods</h4>Patients aged 18 years or older with a confirmed CF diagnosis and percent predicted FEV<sub>1</sub> (ppFEV<sub>1</sub>) of 40 to 90 were randomized to lum  ...[more]

Similar Datasets

| S-EPMC5440888 | biostudies-literature
| S-EPMC7780982 | biostudies-literature
| S-EPMC6366006 | biostudies-literature
| S-EPMC4764353 | biostudies-literature
| S-EPMC5495103 | biostudies-literature
| S-EPMC7177453 | biostudies-literature
| S-EPMC5768901 | biostudies-literature
| S-EPMC6291130 | biostudies-literature
| S-EPMC6641998 | biostudies-literature
| S-EPMC3435140 | biostudies-literature